Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10197624 | 0.82 | TDP2 (0.49) | ALDH1A1KDM4EMEN1KMT2AMAPK1 | |
| SCHEMBL5799822 | 0.82 | GAA (0.44) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL25072493 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL3355386 | 0.82 | HSD17B10 (0.51) | ALDH1A1KDM4EHSD17B10MAPTTSHR | |
| SCHEMBL6977571 | 0.81 | ALDH1A1 (0.49) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL4308779 | 0.80 | MEN1 (0.49) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL5672450 | 0.79 | PARP1 (0.60) | ALDH1A1PARP1MEN1KMT2AHSD17B10 | |
| SCHEMBL7823120 | 0.78 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2AHSD17B10MAPK1 | |
| SCHEMBL7920748 | 0.78 | NR3C1 (0.46) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL1398633 | 0.77 | PARP1 (0.57) | ALDH1A1PARP1MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| WO-2016006593-A1 | NOVEL BENZOXAZINE DERIVATIVE AND MEDICINE COMPRISING SAME | 国立研究開発法人国立長寿医療研究センター | 2016-01-14 | — | — | WO | disclosed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
| WO-2009128262-A1 | QUINOLONE DERIVATIVE AND USE THEREOF | 武田薬品工業株式会社 (JP) | 2009-10-22 | — | — | WO | disclosed |
| EP-0894796-B1 | Imidazolines substituted with a heterocyclic ring as alpha-2 antagonists | ADIR (FR) | 2001-06-06 | — | — | EP | disclosed |
| US-6057317-A | Heterocyclic compounds | ADIR ET COMPAGNIE (FR) | 2000-05-02 | — | — | US | disclosed |
| EP-0894796-A1 | Imidazolines substituted with a heterocyclic ring as alpha-2 antagonists | ADIR ET COMPAGNIE (FR) | 1999-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | ALDH1A1 4553/4885KDM4E 167/4885PARP1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.